PepGen Ltd (PEPG) - Cash Flow Conversion Efficiency
Based on the latest financial reports, PepGen Ltd (PEPG) has a cash flow conversion efficiency ratio of -0.107x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-15.85 Million) by net assets ($147.44 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See PepGen Ltd balance sheet quality to measure how much of total assets are equity-financed.
PepGen Ltd - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how PepGen Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore debt repayment capacity of PepGen Ltd to assess how comfortably operating cash covers total debt obligations.
PepGen Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PepGen Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jeju Beer Co. Ltd.
KQ:276730
|
-0.248x |
|
AMPACS Corp.
TW:6743
|
0.174x |
|
Om Holdings Ltd
AU:OMH
|
-0.146x |
|
Atlas Salt Inc
V:SALT
|
-0.063x |
|
GDB Holdings Bhd
KLSE:0198
|
0.267x |
|
Reliance Industrial Infrastructure Limited
NSE:RIIL
|
-0.028x |
|
Hanpin Electron Co Ltd
TW:2488
|
0.000x |
|
SYN prop e tech S.A.
SA:SYNE3
|
0.017x |
Annual Cash Flow Conversion Efficiency for PepGen Ltd (2019–2025)
The table below shows the annual cash flow conversion efficiency of PepGen Ltd from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see PEPG company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $147.44 Million | $-81.64 Million | -0.554x | +20.27% |
| 2024-12-31 | $118.62 Million | $-82.37 Million | -0.694x | -9.12% |
| 2023-12-31 | $108.42 Million | $-69.00 Million | -0.636x | -92.89% |
| 2022-12-31 | $179.63 Million | $-59.27 Million | -0.330x | -94.31% |
| 2021-12-31 | $133.09 Million | $-22.60 Million | -0.170x | -0.46% |
| 2020-12-31 | $9.77 Million | $-1.65 Million | -0.169x | +26.15% |
| 2019-12-31 | $3.87 Million | $-885.00K | -0.229x | -- |
About PepGen Ltd
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatm… Read more